3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
63
Cardiovascular Diseases
3
Neoplasms
2
Stage II Prostate Adenocarcinoma
1
Sarcopenia
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatectomy
1
Prostate Cancer With ≤10 Bone Metastases
1
Prostate Cancer Metastatic Disease
1
Prostate Cancer Metastatic
1
Osteoporosis
1
Oligometastatic Prostate Carcinoma
1
Obesity
1
Non-alcoholic Fatty Liver Disease
1
Neoplasm Metastasis
1
Metastatic Neuroendocrine Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Metabolic Syndrome
1
Metabolic Diseases
1
Eunuchism
1
Diabetes Mellitus
1
Dementia
1
Cognitive Dysfunction
1
Advanced Prostate Cancer
1
Interventions
Goserelin
2
radium Ra 223 dichloride
1
enzalutamide
1
bicalutamide
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
Radiosurgery
1
Leuprolide
1
Gonadotropin-Releasing Hormone
1
Docetaxel
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Prostate Cancer
×
Gonadotropin-Releasing Hormone
×
Genitourinary
×
Clear all
NCT02234089
2019-07-05
ProComD
Ferring Pharmaceuticals
Completed
461 enrolled